Activation of mechanosensitive ion channel TRPV4 normalizes tumor vasculature and improves cancer therapy
Adapala, Ravi K.
Thoppil, Roslin J.
Dudley, Andrew C.
Meszaros, J. Gary
Chilian, William M.
Thodeti, Charles K.Note: Order does not necessarily reflect citation order of authors.
MetadataShow full item record
CitationAdapala, R. K., R. J. Thoppil, K. Ghosh, H. Cappelli, A. C. Dudley, S. Paruchuri, V. Keshamouni, et al. 2016. “Activation of mechanosensitive ion channel TRPV4 normalizes tumor vasculature and improves cancer therapy.” Oncogene 35 (3): 314-322. doi:10.1038/onc.2015.83. http://dx.doi.org/10.1038/onc.2015.83.
AbstractTumor vessels are characterized by abnormal morphology and hyper-permeability that together cause inefficient delivery of chemotherapeutic agents. Although VEGF has been established as a critical regulator of tumor angiogenesis, the role of mechanical signaling in the regulation of tumor vasculature or tumor endothelial cell (TEC) function is not known. Here, we show that the mechanosensitive ion channel TRPV4 regulates tumor angiogenesis and tumor vessel maturation via modulation of TEC mechanosensitivity. We found that TEC exhibit reduced TRPV4 expression and function, which is correlated with aberrant mechanosensitivity towards ECM stiffness, increased migration and abnormal angiogenesis by TEC. Further, syngeneic tumor experiments revealed that the absence of TRPV4 induced increased vascular density, vessel diameter and reduced pericyte coverage resulting in enhanced tumor growth in TRPV4 KO mice. Importantly, overexpression or pharmacological activation of TRPV4 restored aberrant TEC mechanosensitivity, migration and normalized abnormal angiogenesis in vitro by modulating Rho activity. Finally, a small molecule activator of TRPV4, GSK1016790A, in combination with anti-cancer drug Cisplatin, significantly reduced tumor growth in WT mice by inducing vessel maturation. Our findings demonstrate TRPV4 channels to be critical regulators of tumor angiogenesis and represent a novel target for anti-angiogenic and vascular normalization therapies.
Citable link to this pagehttp://nrs.harvard.edu/urn-3:HUL.InstRepos:27822284